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Abstract 
Results from clinical trials can be susceptible to bias if investigators choose their analysis approach after 
seeing trial data, as this can allow them to perform multiple analyses and then choose the method that 
provides the most favourable result (commonly referred to as ‘p-hacking’). Pre-specification of the 
planned analysis approach is essential to help reduce such bias, as it ensures analytical methods are 
chosen in advance of seeing the trial data. For this reason, guidelines such as SPIRIT (Standard Protocol 
Items: Recommendations for Interventional Trials) and ICH-E9 (International Conference for 
Harmonisation of Technical Requirements for Pharmaceuticals for Human Use) require the statistical 
methods for a trial’s primary outcome be pre-specified in the trial protocol. However, pre-specification 
is only effective if done in a way that does not allow p-hacking. For example, investigators may pre-
specify a certain statistical method such as multiple imputation, but give little detail on how it will be 
implemented. Because there are many different ways to perform multiple imputation, this approach to 
pre-specification is ineffective, as it still allows investigators to analyse the data in different ways before 
deciding on a final approach. In this article we describe a five-point framework (the Pre-SPEC 
framework) for designing a pre-specified analysis approach that does not allow p-hacking. This 
framework was designed based on the principles in the SPIRIT and ICH-E9 guidelines, and is intended to 
be used in conjunction with these guidelines to help investigators design the statistical analysis strategy 
for the trial’s primary outcome in the trial protocol.   
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Introduction 
Results from clinical trials depend upon the statistical methods used for analysis (1-5). Different 
methods of analysis applied to the same trial can lead to different conclusions around effectiveness and 
safety (1-14). Therefore, results from clinical trials can be susceptible to bias if investigators choose their 
analysis approach after seeing trial data, as this can allow them to perform multiple analyses and then 
choose the approach that provides the most favourable result. This is commonly referred to as ‘p-
hacking’, and can lead to bias in treatment effect estimates, confidence intervals, and p-values (1-5, 7-
10, 12, 15). Pre-specification of the planned analysis approach is therefore essential to help reduce such 
bias, as it ensures that analytical methods are chosen in advance of seeing the trial data (1-5, 7, 9, 10, 
12). The SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) and ICH-E9 
(International Conference for Harmonisation of Technical Requirements for Pharmaceuticals for Human 
Use) guidelines require that the method of analysis for the trial’s primary outcome be pre-specified in 
the trial protocol (1, 3, 4).  
 
However, pre-specification is only effective if done in a way that does not allow p-hacking. For example, 
investigators may pre-specify a certain statistical method, such as multiple imputation to handle missing 
data, but give little detail on how it will be implemented. However, there are many different ways to 
implement multiple imputation, such as including different variables in the imputation model, imputing 
under different statistical models, etc. Therefore, this approach to pre-specification is ineffective, as it 
still allows investigators to analyse the data in many different ways before deciding on a final approach. 
This issue of ‘incomplete’ pre-specification, where methods are pre-specified to some extent but the 
specification still allows for some degree of p-hacking, is common in clinical trials (table 1) (2-5). For 
example, two reviews which examined trial protocols found that 11-20% of protocols did not specify the 
analysis model that would be used for the primary outcome, 42% did specify the model but omitted 
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essential detail on how the model would be implemented, and 19% specified an approach that would 
allow the investigators to subjectively choose the final analysis model after seeing the trial data (2, 5).  
 
The SPIRIT and ICH-E9 documents contain guidance on what statistical content should be included in the 
trial protocol (1, 4), and there are also guidelines for the content of Statistical Analysis Plans (9). These 
guidance documents contain some statistical principles which help to limit p-hacking (e.g. requiring that 
when multiple analysis strategies are planned, one of them is identified as the primary analysis), 
however the primary aim of these guidelines is to describe what information should be included in the 
protocol or Statistical Analysis Plan, rather than describe exactly how the analysis should be designed. As 
such, these guidelines do not offer a prescriptive approach for how analysis strategies should be 
designed in order to limit p-hacking. In this article, we describe a framework for how a statistical analysis 
strategy could be designed to ensure it does not allow p-hacking (i.e. so that no part of the statistical 
methods can be chosen after seeing the trial data in order to ‘improve’ results) (2-4). This framework 
was developed to be consistent with the statistical principles outlined in the SPIRIT and ICH-E9 
guidelines (a comparison is shown in Additional file 1: Table S1), and is intended to be used in 
conjunction with these guidelines (1, 3, 4) to help investigators design the statistical analysis strategy for 
the trial’s primary outcome in the trial protocol.  
 
The Pre-SPEC framework  
We now outline the Pre-SPEC framework (box 1). The five points are: (1) Pre-specify before recruitment 
to the trial begins; (2) Specify a single primary analysis strategy; (3) Plan each aspect of the analysis; (4) 
Enough detail should be provided so that a third party could independently perform the analysis; and (5) 
Adaptive analysis strategies should use deterministic decision rules. We expand on each of these points 
below. 
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Pre-specify the analysis strategy before recruitment to the trial begins 
Pre-specifying the analysis strategy before the trial begins ensures the choice of methods is not 
influenced by any trial data. This can give readers confidence that trial results are not due to p-hacking 
(1, 3, 4), as they will generally have no way to verify that analyses specified after the trial began were 
not based on trial data.  
 
Pre-specifying the analysis approach for the trial’s primary outcome in the protocol before the trial 
begins is a requirement of both the SPIRIT and ICH-E9 guidelines (see Additional file 1: Table S1). For 
instance, ICH-E9 states that “… the principal features of its proposed statistical analysis should be clearly 
specified in a protocol written before the trial begins”, and “… the principal features of the eventual 
statistical analysis of the data should be described in the statistical section of the protocol. This section 
should include all the principal features of the proposed confirmatory analysis of the primary variable(s) 
and the way in which anticipated analysis problems will be handled” (1), while SPIRIT states “The 
planned methods of statistical analysis should be fully described in the protocol” and “The protocol 
should indicate explicitly each intended analysis comparing study groups. An unambiguous, complete, 
and transparent description of statistical methods facilitates execution, replication, critical appraisal, and 
the ability to track any changes from the original pre-specified methods” (4).  
 
Specify a single primary analysis strategy 
Specifying a single primary analysis strategy ensures investigators cannot perform multiple analyses and 
then selectively report the most favourable as their main approach. There are often valid reasons to 
specify additional methods of analysis, for instance to answer different questions about the intervention 
(e.g. the effect of a treatment policy vs the effect if everyone adheres (16)), or to assess the robustness 
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of the main results to different assumptions about the data (e.g. sensitivity analyses for missing data 
(17)). In these instances, a single approach should be clearly labelled as the primary analysis strategy, 
with other approaches identified as sensitivity or supplementary analyses as appropriate (1, 3, 4).   
 
Plan each aspect of the statistical analysis  
Omission of a particular aspect from the analysis strategy could allow investigators to run multiple 
analyses for that aspect, and selectively report the most favourable. For example, if the analysis 
population is not specified, investigators could run both an intention-to-treat and per-protocol analysis, 
and present whichever is most favourable.  
 
The minimum set of essential aspects to cover are: 
 Analysis population  
 Statistical model  
 The use of covariates  
 Handling of missing data 
 
However, for many trials there will be additional aspects to cover; for instance, a non-inferiority trial 
would need to specify the non-inferiority margin.  
 
It is also useful to specify the target estimand (16) and what information will be presented from the 
analysis, such as the level of the confidence interval and the threshold for statistical significance if 
applicable.    
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Enough detail should be provided so that a third party could independently perform the analysis  
There is often a substantial amount of detail required to implement an analysis. For example, using 
multiple imputation for missing data requires specification of the method of imputing data; this includes 
specifying which variables are included in the imputation model (and how they are included), whether 
multivariate normal, chained equations or some other imputation approach is used, the number of 
imputed datasets to be used, and how imputed datasets will be combined. Simply stating that multiple 
imputation will be used is not sufficient, as this allows the investigator to carry out multiple analyses 
based on different imputation approaches, each of which could give a different result.  
 
Fully pre-specifying these details to such a degree that a third party could independently perform the 
analysis helps to ensure investigators cannot perform multiple analyses. A good test of whether there is 
sufficient detail is to write out the statistical code that would be used to implement the analysis in a 
statistical software program; if investigators are unable to write out their planned code, this likely 
means the analysis strategy is not sufficiently well specified. This code could be tested on a simulated 
(fake) dataset to ensure if performs as intended.  
 
An additional benefit to providing this code as a supplement to the description of the planned analysis in 
the protocol is that it leaves no room for ambiguity, and ensures all necessary detail is provided (18). 
 
 
Adaptive analysis strategies should use deterministic decision rules  
Sometimes investigators use adaptive analysis strategies, where some aspect of the final analysis is 
chosen based on the trial data. For instance, they may specify that either multiple imputation or a 
complete case analysis will be used depending on the level of missing data. Many clinical trials will not 
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require such decision rules, as there will often be an available analysis approach which can provide valid 
results under minimal assumptions about the data. However, investigators may find these rules useful in 
certain settings where their preferred approach will depend on some features of the data, which are not 
known in advance.  
 
Adaptive analysis strategies can be problematic if the decision rules are subjective, as this allows 
investigators to perform each potential analysis and selectively report the most favourable. For 
example, without a clear rule about when to use multiple imputation vs. complete cases, investigators 
could perform both and then select whichever gives a ‘better’ result.  
 
In order to prevent decisions from being driven by results, adaptive analysis strategies should use 
deterministic decision rules for selection of the final analysis approach. A decision rule is deterministic if 
two different people are guaranteed to get the exact same result by following the rule. This removes the 
investigators ability to influence decisions, and will therefore ensure results cannot be p-hacked. In the 
example above, investigators could specify that multiple imputation will be used if the level of missing 
outcome data is >5%, and a complete case analysis will be used otherwise.  
 
We note that in many instances adaptive analysis strategies can lead to biased estimates or incorrect 
standard errors even when decision rules are fully deterministic. For example, this occurs when using 
stepwise selection to choose which covariates to adjust for; when using a test for carryover to 
determine the final analysis model in a crossover design; or when using a test for interaction to 
determine the final analysis model for a factorial trial (19-21). Therefore, caution should be applied 
when considering adaptive strategies, even if deterministic decision rules are planned. 
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Example  
We now illustrate our framework in an example. Consider the following analysis section from a trial 
protocol for a continuous primary outcome measured at multiple follow-up time-points: 
 
“Primary analyses will be undertaken on an intention-to-treat basis, including all participants as 
randomised, regardless of treatment actually received. The intervention group will be compared with the 
control group using a planned contrast of change from baseline to the week 12 endpoint using a mixed-
model repeated measures analysis. Stratification variables will be evaluated and retained in analyses 
where they are measured as significant or quasi-significant. Transformation of outcomes, including 
categorisation, may be undertaken to meet distributional assumptions and accommodate outliers.” 
 
Evaluating whether the analysis approach is designed to prevent p-hacking 
This analysis approach meets our first two points; it was described in the trial protocol before 
recruitment began, and consists of a single overall analysis strategy.  
 
For our third point, the analysis approach covers three analysis aspects (population, analysis model, 
covariates), however it does not specify how missing data will be handled. We can guess that 
participants with missing outcome data at all follow-up time-points will be excluded from the analysis, 
however this is not entirely clear.  
 
For our fourth point, there is insufficient detail for a third party to independently replicate the analysis 
model; there are numerous ways to implement a mixed-model repeated measures analysis (for 
instance, different approaches to specifying random-effects, or different correlation structures to model 
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the correlation between outcomes from the same participant at different time points), and it is not clear 
which approach the authors intend to use.  
 
For our fifth point, the authors plan to use an adaptive analysis strategy for two components; which 
stratification variables to include in the analysis, and whether to transform the outcome (and if so, 
which transformation to use). In both instances, they do not include deterministic decision rules on how 
the final analysis approach should be decided (e.g. for stratification variables, there is no definition of 
what quasi-significant means). Therefore, this strategy would allow investigators to perform multiple 
analyses on the final trial data before choosing their preferred approach.  
 
Overall, the specified analysis approach could allow investigators to implement a number of different 
analysis strategies (relating to handling of missing data, the analysis model, covariates, and 
transformation of the outcome) and present the most favourable result. As such, although this approach 
has been pre-specified, it still allows p-hacking.   
 
Modifying the analysis approach so it is designed to prevent p-hacking using the Pre-SPEC framework 
We can modify the approach described in the previous section so that it does not allow p-hacking by 
resolving the issues relating to points 3-5 above. First, we could explicitly state that the analysis will use 
all available follow-up data; participants with an available outcome from at least one follow-up time 
point will be included in the analysis, and participants with missing outcome data at all follow-up time 
points will be excluded from the analysis. 
 
Second, we could provide additional information on how the analysis model will be implemented; for 
instance, we could specify a linear mixed-effects model with an unstructured correlation matrix for 
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observations at different time-points, estimated using restricted maximum likelihood. We could 
supplement this description by including the planned statistical code to remove any ambiguity from our 
description (see below for example code for the statistical package Stata).  
 
Finally, we need to resolve the issues around the adaptive analysis strategies related to the stratification 
variables and the transformation of the outcome. In this scenario, it is unlikely that the adaptive 
strategies are necessary, or even beneficial. All stratification variables should be included in the model 
regardless of statistical significance, as failure to do so can lead to incorrect confidence intervals and p-
values (22, 23). Furthermore, linear regression models are usually very robust to violations of 
distributional assumptions (24), and transformation can lead to issues of interpretability (in particular, 
categorisation could lead to a substantial reduction in power (25)). Therefore, the simplest way to 
resolve this issue is to remove the adaptive part, and use a strategy which includes all stratification 
variables in the model and does not consider transformations of the outcome. This approach would 
guarantee valid results under minimal assumptions about the data, which are easily interpretable. If an 
adaptive strategy was deemed necessary, then a deterministic decision rule would need to be specified, 
for example by giving the exact p-value threshold for retaining stratification variables in the model 
(though we note this approach can be problematic even if fully pre-specified (21)).  
 
Incorporating these changes, we could re-write the planned analysis strategy as follows: 
 
Primary analyses will be undertaken on an intention-to-treat basis, including all participants as 
randomised, regardless of treatment actually received. The analysis will use all available outcome data; 
participants with an available outcome from at least one follow-up time point will be included in the 
analysis, and participants with no recorded outcomes will be excluded from the analysis. The intervention 
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group will be compared with the control group using a planned contrast of change from baseline to the 
week 12 endpoint and will be fit using a linear mixed-model which includes outcomes at all time-points in 
the model. The model will use an unstructured correlation matrix for observations at different time 
points, and will be fit using restricted maximum likelihood. The model will include treatment group, time 
point, a treatment-by-time interaction, and the stratification variables as fixed factors. This analysis will 
be implemented using the following Stata code: 
 
mixed outcome treat_group i.time_point treat_group#i.time_point strat1 
strat2 || patient_id:, res(unstructured, t(time_point)) noconstant 
reml 
 
lincom treat_group+treat_group#12.time_point  
 
Where ‘outcome’ refers to the primary outcome (change from baseline), ‘treat_group’ to the treatment 
group, ‘time_point’ refers to the follow-up time-point, ‘treat_group#i.time_point’ refers to the treatment 
group by follow-up time-point interaction, ‘strat1’ and ‘strat2’ refer to the stratification variables and 
‘participant_id’ is a unique ID for participant. The treatment effect at week 12 (primary outcome) is 
estimated using the Stata code: lincom treat_group+treat_group#12.time_point  
 
We note that Stata automatically excludes participants with no recorded outcomes from the analysis, 
and so does not require additional code to perform this step. Further, we note that the above strategy is 
not necessarily the optimal statistical approach, but is used simply to illustrate how the original 
approach could be fully pre-specified.  
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Discussion 
Pre-specification of the planned statistical analysis approach can help to help reduce bias from p-hacking 
in clinical trials, as it ensures analytical methods are chosen in advance of seeing the trial data. However, 
‘incomplete’ pre-specification, which still allows some degree of p-hacking, is common in clinical trials 
(2, 5). Pre-SPEC is a framework that describes how a statistical analysis strategy could be designed to 
ensure it does not allow p-hacking. 
 
This framework was designed to be consistent with the SPIRIT and ICH-E9 guidelines (1, 4), and is 
intended to be used in conjunction with these and other guidelines (9). The SPIRIT and ICH-E9 guidelines 
require the analysis strategy for a trial’s primary outcome be documented in the trial protocol, and as 
such, the Pre-SPEC framework is intended to help investigators design the analysis strategy for the trial’s 
primary outcome in the trial protocol. Our intention is not for the use of this framework be mandated, 
but rather for it to provide guidance for those who wish to design a statistical analysis approach which 
both (i) does not allow p-hacking; and (ii) can be seen by others to not allow p-hacking.  
 
The statistical analysis approach for the trial’s primary outcome is usually specified well in advance of 
the trial start date, as it is often required for grant application or the sample size calculation. Therefore, 
this information will usually be available to include in the trial protocol. However, for trials for which this 
information is not known at the protocol stage, and where investigators feel that specifying this 
information would pose an insurmountable barrier to the timely start of the trial, then investigators 
should specify the planned analysis approach for the primary outcome as soon after the trial has begun 
as possible. For these trials, it may be difficult for readers to determine whether the planned analysis 
approach was specified before investigators had access to unblinded trial data, and so accurate 
reporting around when trial investigators and statisticians received data, and whether they were blinded 
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to treatment allocation codes within the dataset, is essential to allow transparent evaluation of results 
(26, 27).  
 
Although this framework was developed with a trial’s primary outcome in mind, it could also be used for 
secondary outcomes. As above, where investigators feel that specifying this information would pose an 
insurmountable barrier to the timely start of the trial, then investigators should simply specify the 
planned analysis approach as soon after the trial has begun as possible. Importantly, we note that our 
framework does not require that a detailed Statistical Analysis Plan be written before the trial begins.  
 
We note that the Pre-SPEC framework is not intended to preclude changes, or force investigators to 
stick with an analysis strategy they feel is no longer appropriate. There are sometimes good reasons for 
investigators to change their statistical methods during the course of the trial, for instance because of an 
advance in statistical methodology or the implementation of new methods in statistical software 
packages. Instead, if it is anticipated beforehand that the preferred method of analysis may depend on 
some aspect of the trial data (for instance, the distribution of outcome data), then the manner in which 
this decision will be made should be pre-specified; and, if the analysis strategy needs to change due to 
an unanticipated issue (for instance, the occurrence of unanticipated intercurrent events (28), or new 
methodology becoming available in statistical software packages), then these changes should be 
documented and explained (26). Instead of preventing useful or necessary changes, Pre-SPEC simply 
increases transparency around the process; as stated in the SPIRIT guidelines, “An unambiguous, 
complete, and transparent description of statistical methods facilitates execution, replication, critical 
appraisal, and the ability to track any changes from the original pre-specified methods.” (4) 
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We note that transparency around the statistical methods used in clinical trials is increasing, and there 
are initiatives in place to further increase transparency (for example, those conducted by the UKCRC 
CTU network, https://www.ukcrc-ctu.org.uk/). However, there is still a long way to go; evidence shows 
that the statistical methods for the trial’s primary outcome are often poorly specified in both trial 
protocols (5, 26, 27) and Statistical Analysis Plans (26); that protocols and Statistical Analysis Plans are 
often not made publicly available, or are only done so after they may have already been modified during 
the course of the trial (26, 27, 29); undisclosed changes to the planned analysis approach are frequent 
(2, 26, 27); and reporting around data access and blinding status of statisticians is often poor (26, 27), 
hampering the ability of readers to evaluate whether changes have been made based on unblinded trial 
data. Pre-SPEC can play a part, alongside other initiatives, to help increase transparency in clinical trials, 
and resolving some of the issues outlined above.  
 
Conclusion 
Use of the Pre-SPEC framework can help ensure that statistical analyses are designed so they do not 
allow p-hacking.  
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Table 1: Common issues in pre-specifying statistical analysis approaches in clinical trial protocols 
  Estimated prevalence 
Issue Problems associated 
with issue 
Aspect Prevalencea 
Omitting an aspect of the 
analysis approach 
 
 
 
 
Investigators could run 
multiple analyses, and 
selectively report the 
most favourable 
Analysis population:  
Analysis model:  
Covariates:  
Missing data:  
27-47% 
11-20% 
27% 
66-77% 
Insufficient detail around 
an aspect of the analysis 
approach 
Analysis population:  
Analysis model: 
Covariates: 
Missing data: 
64% 
42% 
23% 
17%b 
Analysis approach allows 
some aspects of the final 
analysis to be subjectively 
chosen based on trial data 
Analysis model: 
Covariates: 
 
19% 
8% 
Multiple analysis 
approaches specified, 
without one being 
identified as the primary 
Investigators could 
selectively report the 
most favourable result, 
or to elevate its 
importance compared to 
less favourable results. 
Analysis population: 
Analysis model: 
Covariates: 
Missing data: 
11% 
11% 
9% 
2% 
 
a Based on references (5) and (2); one study evaluated protocols and published results for 70 
randomised trials approved by the ethics committees for Copenhagen and Frederiksberg, Denmark in 
1994-5; the other study evaluated 100 protocols of randomised trials indexed in PubMed November 
2016. 
b 15/99 protocols gave insufficient detail around how they planned to implement multiple imputation, 
2/99 protocols but gave insufficient detail around their planned inverse probability weighting procedure 
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Box 1 – Framework for pre-specifying a statistical analysis strategy (Pre-SPEC) 
 
Pre-specify before recruitment Pre-specify the analysis strategy before recruitment to the trial 
begins. 
 
Single analysis strategy Specify a single primary analysis strategy. 
 
Plan each aspect  Each aspect of the planned analysis should be covered, 
including analysis population, statistical model, covariates, and 
handling of missing data.   
 
Enough detail Provide sufficient detail to allow a third party to independently 
perform the analysis (ideally through statistical code).  
 
Choices made deterministically  For adaptive analysis strategies which use the trial data to 
inform some aspect of the analysis, use deterministic decision-
rules that prevent analysis choices being driven by results.   
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Additional file 1: Table S1 
Table S1 – Comparison of the Pre-SPEC framework with the SPIRIT and ICH-E9 guidelines 
Pre-SPEC 
framework 
SPIRIT ICH-E9 Comment 
Pre-specify 
before 
recruitment to 
the trial begins 
 “The planned methods of 
statistical analysis should be 
fully described in the protocol” 
 “The protocol should indicate 
explicitly each intended 
analysis comparing study 
groups. An unambiguous, 
complete, and transparent 
description of statistical 
methods facilitates execution, 
replication, critical appraisal, 
and the ability to track any 
changes from the original pre-
specified methods.” 
 “For each clinical trial contributing 
to a marketing application, all 
important details of its design and 
conduct and the principal features 
of its proposed statistical analysis 
should be clearly specified in a 
protocol written before the trial 
begins.” (p5) 
 “When designing a clinical trial the 
principal features of the eventual 
statistical analysis of the data 
should be described in the statistical 
section of the protocol. This section 
should include all the principal 
features of the proposed 
confirmatory analysis of the primary 
variable(s) and the way in which 
anticipated analysis problems will 
be handled.” p23-24 
Both SPIRIT and ICH-E9 state the 
planned statistical analysis 
approach should be pre-specified 
in the protocol. ICH-E9 explicitly 
states this should be done before 
the trial begins; SPIRIT does not 
state this explicitly, but it is 
implied given that the first version 
of the protocol must be 
completed before the trial begins.   
Specify a single 
primary analysis 
strategy. 
 “Results for the primary 
outcome can be substantially 
affected by the choice of 
analysis methods. When 
investigators apply more than 
one analysis strategy for a 
specified primary outcome, 
there is potential for 
inappropriate selective 
reporting of the most 
 “The primary analysis of the primary 
variable should be clearly 
distinguished from supporting 
analyses of the primary or 
secondary variables.” p28 
Both SPIRIT and ICH-E9 state 
explicitly that a single main 
analysis strategy should be 
identified.  
22 
 
interesting result. The protocol 
should prespecify the main 
(“primary”) analysis of the 
primary outcome…” 
 “When both unadjusted and 
adjusted analyses are 
intended, the main analysis 
should be identified (Item 
20a).” 
Plan all aspects 
of the analysis 
(including 
analysis 
population, 
statistical 
model, 
covariates, and 
handling of 
missing data)   
 “The protocol should 
prespecify the main 
(“primary”) analysis of the 
primary outcome (Item 12), 
including the analysis methods 
to be used for statistical 
comparisons (Items 20a and 
20b); precisely which trial 
participants will be included 
(Item 20c); and how missing 
data will be handled (Item 
20c).” 
 “It is important that trial 
investigators indicate in the 
protocol if there is an intention 
to perform or consider 
adjusted analyses, explicitly 
specifying any variables for 
adjustment and how 
continuous variables will be 
handled.” 
 “Protocols should explicitly 
describe which participants will 
be included in the main 
analyses (eg, all randomised 
 “The set of subjects whose data are 
to be included in the main analyses 
should be defined in the statistical 
section of the protocol.” p24 
 “The decision to transform key 
variables prior to analysis is best 
made during the design of the trial 
on the basis of similar data from 
earlier clinical trials. 
Transformations (e.g. square root, 
logarithm) should be specified in the 
protocol and a rationale provided, 
especially for the primary 
variable(s).” p27 
 “The statistical section of the 
protocol should specify the 
hypotheses that are to be tested 
and/or the treatment effects which 
are to be estimated in order to 
satisfy the primary objectives of the 
trial. The statistical methods to be 
used to accomplish these tasks 
should be described for the primary 
(and preferably the secondary) 
variables, and the underlying 
SPIRIT explicitly states that the 
analysis population, analysis 
model, covariates, handling of 
missing data, and any other 
relevant aspects should be 
specified. ICH-E9 explicitly states 
that the analysis population, 
statistical model, covariates, and 
use of transformations for key 
variables should be specified.   
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participants, regardless of 
protocol adherence) and 
define the study group in 
which they will be analysed 
(eg, as randomised).” 
 “The protocol should also state 
how missing data will be 
handled in the analysis and 
detail any planned methods to 
impute (estimate) missing 
outcome data, including which 
variables will be used in the 
imputation process (if 
applicable).” 
 “Finally, different trial designs 
dictate the most appropriate 
analysis plan and any 
additional relevant information 
that should be included in the 
protocol. For example, cluster, 
factorial, crossover, and 
within-person randomised 
trials require specified 
statistical considerations, such 
as how clustering will be 
handled in a cluster 
randomised trial.” 
statistical model should be made 
clear. Estimates of treatment effects 
should be accompanied by 
confidence intervals, whenever 
possible, and the way in which these 
will be calculated should be 
identified. A description should be 
given of any intentions to use 
baseline data to improve precision 
or to adjust estimates for potential 
baseline differences, for example by 
means of analysis of covariance.” 
p27 
 “All effects to be fitted in the 
analysis (for example in analysis of 
variance models) should be fully 
specified… . The same 
considerations apply to the set of 
covariates fitted in an analysis of 
covariance.“ p28 
 “The primary variable(s) is often 
systematically related to other 
influences apart from treatment. 
For example, there may be 
relationships to covariates such as 
age and sex, or there may be 
differences between specific 
subgroups of subjects such as those 
treated at the different centres of a 
multicentre trial. In some instances 
an adjustment for the influence of 
covariates or for subgroup effects is 
an integral part of the planned 
analysis and hence should be set 
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out in the protocol. Pre-trial 
deliberations should identify those 
covariates and factors expected to 
have an important influence on the 
primary variable(s), and should 
consider how to account for these in 
the analysis in order to improve 
precision and to compensate for any 
lack of balance between treatment 
groups.” p28 
Enough detail 
should be 
provided so that 
a third party 
could 
independently 
perform the 
analysis 
 “It is important that trial 
investigators indicate in the 
protocol if there is an intention 
to perform or consider 
adjusted analyses, explicitly 
specifying any variables for 
adjustment and how 
continuous variables will be 
handled.” 
 “Protocols should explicitly 
describe which participants will 
be included in the main 
analyses (eg, all randomised 
participants, regardless of 
protocol adherence) and 
define the study group in 
which they will be analysed 
(eg, as randomised).” 
 “The ambiguous use of labels 
such as “intention to treat” or 
“per protocol” should be 
avoided unless they are fully 
defined in the protocol. … 
 “The decision to transform key 
variables prior to analysis is best 
made during the design of the trial 
on the basis of similar data from 
earlier clinical trials. 
Transformations (e.g. square root, 
logarithm) should be specified in the 
protocol and a rationale provided, 
especially for the primary 
variable(s).” p27 
 “The statistical section of the 
protocol should specify the 
hypotheses that are to be tested 
and/or the treatment effects which 
are to be estimated in order to 
satisfy the primary objectives of the 
trial. The statistical methods to be 
used to accomplish these tasks 
should be described for the primary 
(and preferably the secondary) 
variables, and the underlying 
statistical model should be made 
clear. Estimates of treatment effects 
should be accompanied by 
Both SPIRIT and ICH-E9 state that 
certain aspects of the analysis 
should be explicitly or fully 
described (e.g. analysis 
population, covariates, handling 
of missing data, etc).  
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Other ambiguous labels such 
as “modified intention to 
treat” are also variably defined 
from one trial to another.” 
 “The protocol should also state 
how missing data will be 
handled in the analysis and 
detail any planned methods to 
impute (estimate) missing 
outcome data, including which 
variables will be used in the 
imputation process (if 
applicable).” 
 
confidence intervals, whenever 
possible, and the way in which these 
will be calculated should be 
identified. A description should be 
given of any intentions to use 
baseline data to improve precision 
or to adjust estimates for potential 
baseline differences, for example by 
means of analysis of covariance.” 
p27 
 “All effects to be fitted in the 
analysis (for example in analysis of 
variance models) should be fully 
specified… . The same 
considerations apply to the set of 
covariates fitted in an analysis of 
covariance.“ p28 
 “The primary variable(s) is often 
systematically related to other 
influences apart from treatment. 
For example, there may be 
relationships to covariates such as 
age and sex, or there may be 
differences between specific 
subgroups of subjects such as those 
treated at the different centres of a 
multicentre trial. In some instances 
an adjustment for the influence of 
covariates or for subgroup effects is 
an integral part of the planned 
analysis and hence should be set 
out in the protocol. Pre-trial 
deliberations should identify those 
covariates and factors expected to 
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have an important influence on the 
primary variable(s), and should 
consider how to account for these in 
the analysis in order to improve 
precision and to compensate for any 
lack of balance between treatment 
groups.” p28 
Adaptive 
analysis 
strategies 
should use 
deterministic 
decision rules 
 “It is important that trial 
investigators indicate in the 
protocol if there is an intention 
to perform or consider 
adjusted analyses… . It may not 
always be clear, in advance, 
which variables will be 
important for adjustment. In 
such situations, the objective 
criteria to be used to select 
variables should be 
prespecified.” 
 “The particular statistical model 
chosen should reflect the current 
state of medical and statistical 
knowledge about the variables to be 
analysed as well as the statistical 
design of the trial. All effects to be 
fitted in the analysis (for example in 
analysis of variance models) should 
be fully specified, and the manner, if 
any, in which this set of effects 
might be modified in response to 
preliminary results should be 
explained.” p28 
SPIRIT advocates objective 
decision rules in a single specific 
instance (if covariates are to be 
chosen based on trial data). ICH-
E9 states that the way the 
analysis might be modified in 
response to preliminary results 
should be specified. To the extent 
that adaptive analysis strategies 
are mentioned, both imply that 
pre-specified deterministic 
decision rules should be used. 
 
 
 
 
 
